evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

228 questions · 231 findings · 20 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 32 · 13.9%GRADE not reported 4 · 1.7%Very low 46 · 19.9%Low 80 · 34.6%Moderate 53 · 22.9%High 16 · 6.9%

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Progression‐free survival · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Overall survival (OS) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Progression‐free survival (PSF) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… probably leads to lower any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Hysterectomy (radical) with neoadjuvant chemotherapy vs chemoradiotherapy alone

Death (all causes) · women with locally advanced cervical cancer

Hysterectomy (radical) with neoadjuvant chemotherapy showed no clear difference in overall survival Median compared with chemoradiotherapy alone (moderate certainty).

1 finding from 1 review

Hysterectomy (radical) with neoadjuvant chemotherapy vs chemoradiotherapy alone

SAEs and toxicity · women with locally advanced cervical cancer

It is very uncertain whether hysterectomy (radical) with neoadjuvant chemotherapy changes SAEs and toxicity compared with chemoradiotherapy alone (very low certainty).

1 finding from 1 review